Population Pharmacokinetics of Clesrovimab in Preterm and Full‐Term Infants

Documenti analoghi

• Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib
  di: Jatinder Kaur Mukker, et al.
  Pubblicazione: (2025)
• Population Pharmacokinetics of siRNA JNJ ‐73763989 in Healthy Participants and Patients With Chronic Hepatitis B
  di: Tetsuro Ogawa, et al.
  Pubblicazione: (2025)
• A Pooled Population Pharmacokinetic Study of Oral and Intravenous Administration of Clavulanic Acid in Neonates and Infants: Targeting Effective Beta‐Lactamase Inhibition
  di: Stef Schouwenburg, et al.
  Pubblicazione: (2024)
• Impact of COVID‐19 on the Conduct and Design of Clinical Trials: IQ Consortium Perspective
  di: Mohamed‐Eslam F. Mohamed, et al.
  Pubblicazione: (2024)
• Population Pharmacokinetics of Dupilumab in Adults, Adolescents, and Children With Eosinophilic Esophagitis
  di: Jenny‐Hoa Nguyen, et al.
  Pubblicazione: (2026)